Treatment of High-Grade Glioma in the Cerebellum

Initial Management

• The National Comprehensive Cancer Network recommends maximal safe surgical resection as the primary intervention for high-grade gliomas, as extent of resection directly correlates with survival 1, 2, 4
• The British Journal of Cancer suggests that patients with good performance status should undergo maximal safe resection followed by radiotherapy (60 Gy in 1.8-2 Gy fractions) plus concurrent and adjuvant temozolomide 1, 2, 3
• Postoperative MRI should be obtained within 24-72 hours to document extent of resection, as recommended by the Journal of the National Comprehensive Cancer Network 5, 3

Adjuvant Therapy

• The National Comprehensive Cancer Network recommends a standard regimen of concurrent radiotherapy (60 Gy in 1.8-2 Gy fractions) plus temozolomide 75 mg/m² daily for up to 49 days, followed by adjuvant temozolomide 150-200 mg/m² on days 1-5 of each 28-day cycle for 6 cycles 1, 2, 6
• Adjuvant treatment should be initiated within one month of surgery, as recommended by the British Journal of Cancer 1, 2, 4

Molecular Testing

• The National Comprehensive Cancer Network recommends obtaining MGMT promoter methylation status, IDH mutation status, and 1p/19q codeletion testing on surgical specimens 3, 7
• MGMT methylation predicts temozolomide benefit, with methylated tumors showing median survival of 23 months versus 13 months for unmethylated 7

Surveillance and Recurrence

• The Journal of the National Comprehensive Cancer Network recommends MRI brain with and without contrast every 3-4 months to monitor for recurrence 3, 5
• Enrollment in clinical trials is strongly preferred when progression occurs despite initial treatment, as recommended by the National Comprehensive Cancer Network 1, 5, 2

Prognostic Factors

• The National Comprehensive Cancer Network identifies favorable prognostic indicators, including younger age (<50 years), good performance status (Karnofsky ≥70), greater extent of resection, MGMT promoter methylation, IDH mutation, and 1p/19q codeletion 1, 2, 3, 7
• Median survival for glioblastoma is approximately 15 months with standard treatment, extending to 23 months in MGMT-methylated tumors 7